The role of XXXX in the management of @entity3039 .

@entity1 @entity3152 @entity882 @entity548 @entity1503 @entity3039
On consultation, @entity1503 ( @entity1503 ) was offered to @entity1 with @entity3039 ( @entity3039 ) to determine the mode and site of delivery prior to labour. Between January 1989 and December 1993, 41 pregnant @entity1 underwent @entity1503 . All @entity1 had a history of @entity3039 , a platelet count less than 90 K, (+) antiplatelet antibody, and/or @entity882 diagnosed early in pregnancy. @entity1503 was performed at term except in one @entity1 with @entity3152 , who underwent @entity1503 at 31 weeks' gestation. @entity1 with fetal platelet counts greater than 50 K returned to their referring physician for delivery. Records were complete in 39 pregnancies. Fetal blood was successfully obtained in 37 of 39 cases (95 per cent). Fetal platelet counts correlated with neonatal platelet counts in 36 of 37 cases (97 per cent). The interval between @entity1503 and delivery ranged from 0 to 31 days. Six of 37 fetuses (16 per cent) had significant @entity882 (< 50 K). These six @entity1 underwent Caesarean section. Vaginal delivery was recommended in all others. There were two procedure-related complications. There were no cases of @entity548 in any of the neonates. In conclusion, there is a high incidence of @entity882 in @entity1 with @entity3039 . @entity1503 reliably detects @entity882 and is therefore useful in the perinatal planning of the mode and site of delivery.
